Two Sigma Securities’s Oncternal Therapeutics, Inc. Common Stock ONCT Stock Holding History

Two Sigma Securities’s Portfolio ONCT Stock Details ONCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-2,938	Closed	-$31.5K	–	3873
2023 Q4	$31.5K	Buy	2,938 +1,877	+177%	+$13.5K	﹤0.01%	2658
2023 Q3	$6.37K	Buy	+1,061	New	+$7.47K	﹤0.01%	2764
2023 Q1	–	Sell	-2,719	Closed	-$54.4K	–	3451
2022 Q4	$54.4K	Buy	+2,719	New	+$54.1K	﹤0.01%	2149
2022 Q3	–	Sell	-831	Closed	-$18K	–	3245
2022 Q2	$18K	Buy	+831	New	+$18.5K	﹤0.01%	1976
2018 Q4	–	Sell	-161	Closed	-$35K	–	2977
2018 Q3	$35K	Buy	+161	New	+$386K	﹤0.01%	2388

Other funds holding ONCT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

QPW

Quantum Private Wealth Tampa, Florida $390M AUM 58.18% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Richmond Brothers Jackson, Michigan $150M AUM 14.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BJL

Brighton Jones LLC Seattle, Washington $2.37B AUM 16.36% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Two Sigma Securities's ONCT Position: Q1 2024 in Review

Two Sigma Securities sold out of Oncternal Therapeutics, Inc. Common Stock (ONCT) in Q1 2024, closing a stake of 2,938 shares — an estimated $31.5K sold.

Two Sigma Securities first reported a position in ONCT in Q3 2018 and held it in 5 quarters. The position peaked at $54.4K in Q4 2022. 24 funds tracked by Wall St. Rank hold ONCT as of Q1 2024.

Two Sigma Securities reported no remaining Oncternal Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
Two Sigma Securities sold 2,938 Oncternal Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $31.5K.
Two Sigma Securities first reported a position in Oncternal Therapeutics, Inc. Common Stock in Q3 2018 and held it in 5 quarters.
Two Sigma Securities's Oncternal Therapeutics, Inc. Common Stock position peaked at $54.4K in Q4 2022.
24 funds tracked by Wall St. Rank held Oncternal Therapeutics, Inc. Common Stock as of Q1 2024.

Based on Two Sigma Securities's 13F filing for Q1 2024, filed 15 May 2024.